130 related articles for article (PubMed ID: 9434462)
61. [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Li YX; Ding GX; Li QF; Chen L; Hu GL; Ji QH; Wang SJ; Guo Y; Luo R; Hou WK; Wang PN; Zhang NY; Zhang YP; Wang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):211-3. PubMed ID: 18505128
[TBL] [Abstract][Full Text] [Related]
62. Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
Bell PM; Cuthbertson J; Patterson S; O'Harte FP
Diabetes Res Clin Pract; 2011 Mar; 91(3):e68-70. PubMed ID: 21194775
[TBL] [Abstract][Full Text] [Related]
63. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.
Miwa S; Watada H; Ohmura C; Tanaka Y; Kawamori R
Endocr J; 2004 Aug; 51(4):393-8. PubMed ID: 15351795
[TBL] [Abstract][Full Text] [Related]
65. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
66. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
[TBL] [Abstract][Full Text] [Related]
67. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism.
Dimitriadis G; Boutati E; Lambadiari V; Mitrou P; Maratou E; Brunel P; Raptis SA
Eur J Clin Invest; 2004 Jul; 34(7):490-7. PubMed ID: 15255786
[TBL] [Abstract][Full Text] [Related]
68. [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Kawamori R; Kadowaki T; Ishida H
Nihon Rinsho; 2004 Apr; 62(4):831-9. PubMed ID: 15106356
[No Abstract] [Full Text] [Related]
69. Postprandial lipid profile in patients with type 2 diabetes.
Katsiki N; Kolovou G
Curr Med Res Opin; 2014 Jan; 30(1):121. PubMed ID: 24024786
[No Abstract] [Full Text] [Related]
70. Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus.
Yamada S; Watanabe M; Funae O; Atsumi Y; Suzuki R; Yajima K; Nakamura Y; Kawai T; Oikawa Y; Shimada A
Intern Med; 2007; 46(23):1893-7. PubMed ID: 18057760
[TBL] [Abstract][Full Text] [Related]
71. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
[TBL] [Abstract][Full Text] [Related]
72. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
73. [Glinides and glitazones in diabetes treatment. Are they really effective?].
Parhofer KG; Göke B
MMW Fortschr Med; 2002 May; 144(18):34-6, 38-9. PubMed ID: 12422705
[TBL] [Abstract][Full Text] [Related]
74. [Differences between oral antidiabetics].
Bleskestad IH; Birkeland KI
Tidsskr Nor Laegeforen; 2003 Mar; 123(6):808-9. PubMed ID: 12693123
[No Abstract] [Full Text] [Related]
75. N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2.
Shinkai H; Nishikawa M; Sato Y; Toi K; Kumashiro I; Seto Y; Fukuma M; Dan K; Toyoshima S
J Med Chem; 1989 Jul; 32(7):1436-41. PubMed ID: 2738878
[TBL] [Abstract][Full Text] [Related]
76. Acute and long-term effects of nateglinide on insulin secretory pathways.
Ball AJ; Flatt PR; McClenaghan NH
Br J Pharmacol; 2004 May; 142(2):367-73. PubMed ID: 15155541
[TBL] [Abstract][Full Text] [Related]
77. Stimulation of insulin release in hereditarily diabetic rats by mixed molecules formed of nateglinide and a succinic acid ester.
Ladriere L; Bjorkling F; Malaisse WJ
Int J Mol Med; 2000 Jan; 5(1):63-5. PubMed ID: 10601576
[TBL] [Abstract][Full Text] [Related]
78. [Adverse effects of oral hypoglycemic agents].
Mori Y; Sekihara H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():325-31. PubMed ID: 12387013
[No Abstract] [Full Text] [Related]
79. Novartis breached code after doctors say it "invented" a disease.
Ferriman A
BMJ; 2002 Dec; 325(7377):1379. PubMed ID: 15083812
[No Abstract] [Full Text] [Related]
80. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
